RxDoctor Payments DataLook up a doctor →

Hazem Albandar, MD

Neurology · Newburgh, INNPI 1134655491

Payments from drug & device makers

$44,558in general payments, 2019–2025

Across 530 payments — averaging $84.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$22K
  • Livanova USA, Inc.$15K
  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$738
  • SK Life Science, Inc.$580
  • Eisai Inc.$549
  • plus $4K from 30 others

What the payments were for

  • Speaking & faculty fees$28,20063%
  • Travel & lodging$5,14112%
  • Food & beverage$10,93425%
  • Education$2821%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,558 in reported general payments places this provider in the 80th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$103,185
Medicare patients
351
Services billed
1,119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam88$128,373
FycompaPerampanel49$64,558
NayzilamMidazolam52$56,922
AptiomEslicarbazepine Acetate30$50,541
EpidiolexCannabidiol (Cbd)22$49,366
UbrelvyUbrogepant21$30,316
XcopriCenobamate29$28,151
Emgality PenGalcanezumab-Gnlm32$27,445
QuliptaAtogepant19$26,524
Lacosamide145$25,952
VimpatLacosamide13$16,565
Levetiracetam555$16,386
Clobazam27$7,914
Diazepam15$5,425
DilantinPhenytoin Sodium Extended19$3,631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Nayzilam, Vimpat$22,443$201,860153 claims
Eisai Inc.Fycompa$549$64,55849 claims
AbbVieUbrelvy, Qulipta$1,704$56,84040 claims
SK Life Science, Inc.Xcopri$580$28,15129 claims
PfizerDilantin$491$3,63119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 308 neurology providers in Indiana.

Other neurology in Newburgh

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →